Culture Biosciences Secures Series C Funding to Enhance Growth

Culture Biosciences, a prominent player in cloud-based biomanufacturing, has successfully closed its Series C funding round, raising significant capital to enhance its commercial growth. This round, which took place on December 16, 2025, was led by existing investors including Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox. The strong backing from current shareholders underscores their confidence in Culture’s strategic direction and future potential.

The Series C financing will primarily support the expansion of Culture’s cutting-edge hardware product, the Stratyx 250. This advanced system is designed to meet the increasing demands of modern biologics, cell therapy, and sophisticated bioprocess development. By providing scalable, automated, and digitally connected bioprocess capabilities, the Stratyx 250 aims to revolutionize the biomanufacturing landscape.

In addition to hardware advancements, the funding will also facilitate the ongoing development of the company’s AI-powered Console software ecosystem. This innovative software suite is integral to enhancing operational efficiency and providing real-time analytics for users in the biomanufacturing sector.

Culture Biosciences, headquartered in South San Francisco, California, has positioned itself as a leader in the biomanufacturing domain by leveraging cloud technology. The company’s commitment to innovation and efficiency is expected to drive significant growth in the coming years as it continues to address the evolving needs of the industry.

The completion of the Series C round marks a pivotal moment for Culture, enabling it to accelerate its product development initiatives and expand its market reach. As the demand for advanced biomanufacturing solutions continues to grow, Culture is poised to play a crucial role in shaping the future of the field.

With this new influx of capital, Culture Biosciences is not only enhancing its product offerings but also reinforcing its position as a key player in the biomanufacturing industry. The successful funding round reflects a broader trend in the sector, where investor confidence in innovative biotechnologies is on the rise.